Comment on: Rifaximin in the treatment of irritable bowel syndrome. is there a high risk for development of antimicrobial resistance?

J Clin Gastroenterol. 2013 Oct;47(9):814. doi: 10.1097/MCG.0b013e3182951b6c.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Animals
  • Anti-Infective Agents / pharmacology*
  • Humans
  • Irritable Bowel Syndrome / drug therapy*
  • Rifamycins / pharmacology*

Substances

  • Anti-Infective Agents
  • Rifamycins